Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 4.1% After Analyst DowngradeMarket Beat·11 hours agoGLUE-6.90%
Why Monte Rosa Therapeutics (GLUE) Is Down 27.5% After Novo Nordisk’s ZEUS Trial Missed Its GoalSimplywall·2 days ago, 02:13 AMNVO+2.00%GLUE-6.90%
Buy Rating Maintained on Monte Rosa as Diversified Degrader Pipeline and Novartis Partnership Offset ZEUS Cardiovascular SetbackTip Ranks·Jul 31 at 01:45 PMGLUE-6.90%NVS-1.59%
Monte Rosa, BioAge plunge as Novo’s setback casts a shadow over pipelinebusinessinsider·Jul 31 at 01:16 PMBIOA+19.25%GLUE-6.90%
Monte Rosa CSO Sharon Townson disposes of common shares worth $140,297.2PUBT·Jul 7 at 03:42 PMGLUE-6.90%
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 6.9% - Should You Buy?Market Beat·Jul 7 at 01:40 PMGLUE-6.90%BAC+0.86%
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by BrokeragesMarket Beat·Jul 5 at 07:29 AMGLUE-6.90%
Monte Rosa Therapeutics grants inducement awards to new hires, including options for 18,025 shares at $24.02PUBT·Jul 2 at 03:01 PMGLUE-6.90%
Filip Janku Sells 5,407 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) StockMarket Beat·Jul 1 at 04:07 PMGLUE-6.90%
Monte Rosa Therapeutics director Anthony M. Manning disposes of 10,000 common shares worth $231,100PUBT·Jun 30 at 03:06 PMGLUE-6.90%
Monte Rosa Therapeutics (GLUE) Joins Russell Growth Indexes, Is The Upside Already Priced In?Simplywall·Jun 30 at 03:06 AMGLUE-6.90%
Monte Rosa Therapeutics CSO Sharon Townson disposes of 3,000 common shares for $60,000PUBT·Jun 25 at 03:05 PMGLUE-6.90%
